FDLI

Second in a series of discussion on should terminally ill patients get access
to unapproved drugs?

Now Available

Full Transcript from FDLI’s Colloquium #2, From Abigail to Penelope:
Individual to Corporate Rights

Find out what these experts had to say about access to unapproved drugs
for seriously ill patients:

• Janet Woodcock, MD, Deputy Commissioner and Chief Medical Officer at the Food and Drug Administration. 
• Scott Ballenger, a partner at Latham & Watkins in Washington, D.C., and lead attorney in the Abigail Alliance case. 
• D. Bruce Burlington, MD, Executive Vice President of Business Practices and Compliance at Wyeth Pharmaceuticals. 
• John Crowley, President and Chief Executive Officer at Amicus Therapeutics. 
• Philip Katz, a partner at Hogan & Hartson in Washington, D.C. 
• Jonathan Moreno, an ethics professor at the University of Pennsylvania.